Use and Future Investigations of Recombinant and Plasma-Derived Coagulation and Anticoagulant Products in the Neonate

Abstract

Although congenital bleeding disorders can manifest in the newborn period, the most common causes of bleeding and thrombosis in neonates are acquired conditions. Factor concentrates are used for specific diagnoses (hemophilia with inhibitors, specific factor deficiency, von Willebrand disease) and approved indications, and increasingly for off-label indications (bleeding in surgery cardiopulmonary bypass, extracorporeal membrane oxygenation). We will review the approved indications for factor products in the neonate and discuss the evidence and rationale for off-label use of factor products in management of bleeding and thrombosis in the neonate.

Keywords: Antithrombin concentrate; Factor IX concentrate; Factor VIII concentrate; Factor VIIa; Factor XIII concentrate; Fibrinogen concentrate; Protein C concentrate; Prothrombin complex concentrate; Recombinant factor VIIa concentrate; von Willebrand factor concentrate.